(Q96695265)

A Single-center,Open-label, Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (English)

end time

20 February 2021

1 reference

stated in

ClinicalTrials.gov

ClinicalTrials.gov ID

1 reference

The COVID-19 vaccine development landscape

side effect

fever

1 reference

stated in

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

pain

1 reference

stated in

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

fatigue

1 reference

stated in

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

route of administration

intramuscular injection

1 reference

stated in

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

manufacturer

Petrovax

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

21 September 2020

2 references

https://covid-19tracker.milkeninstitute.org/

11 July 2020

11 March 2002

PLA Academy of Military Medical Sciences

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

described by source

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

retrieved

11 July 2020

A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)

1 reference

retrieved

12 July 2020

reference URL

https://covid-19tracker.milkeninstitute.org/

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada

1 reference

retrieved

12 July 2020

reference URL

https://covid-19tracker.milkeninstitute.org/

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

1 reference

based on heuristic

inferred from abstract

A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)

1 reference

based on heuristic

inferred from abstract

A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

retrieved

30 August 2020

A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

retrieved

30 August 2020

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

retrieved

8 October 2020

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

1 reference

reference URL

https://covid-19tracker.milkeninstitute.org/

retrieved

8 October 2020

on focus list of Wikimedia project

WikiProject COVID-19

0 references

Commons category

Convidecia

0 references

Identifiers

0 references

0 references

0 references

Google Knowledge Graph ID

0 references

0 references

0 references

Sitelinks

Wikipedia(20 entries)

Wikibooks(0 entries)

Wikinews(1 entry)

ruwikinews Категория:Конвидеция

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Convidecia